PaxVax and Valneva will market each other's cholera and typhoid vaccines; Scripps wins $4.5M from Gates Foundation for HIV/AIDS vaccine;

> PaxVax and Valneva have entered into an agreement to market their cholera and typhoid vaccines. PaxVax will market Valneva's Dukoral in Italy, Spain and Portugal, and Valneva will market PaxVax's Vivotif in Canada, Sweden, Norway, Denmark and Finland. Release

> The Scripps Research Institute won two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund the development of an HIV/AIDS vaccine. Release

> Gaithersburg, MD-based Vaxin announced the enrollment of its first patient into a Phase I trial of HepTcell, its hepatitis B candidate. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.